The SF268 cell line is a human glioblastoma cell line derived from a brain tumor in a 56-year-old female patient. Glioblastoma, also known as glioblastoma multiforme (GBM), is an aggressive and highly malignant primary brain tumor that arises from glial cells called astrocytes. Glioblastomas are known for their fast growth and poor prognosis, with an average survival time of about 15 months following diagnosis, despite aggressive treatment options.

The SF268 cell line is used as an in vitro model system for studying glioblastoma biology, molecular mechanisms, and potential therapeutics. Researchers have utilized this cell line in various studies to investigate the role of oncogenes, tumor suppressor genes, and signaling pathways in glioblastoma development and progression. Additionally, SF268 cells have been employed to test the efficacy of potential anti-cancer drugs and to study drug resistance mechanisms specific to glioblastoma.

In summary, the SF268 cell line is a valuable tool for researchers working in the field of brain cancer, as it provides insights into the biology and molecular mechanisms underlying glioblastoma and aids in the development and testing of potential therapeutic strategies.